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OBJECTIVE — Recentstudiessuggestthaturicacidmaypredictthedevelopmentofdiabetes
in the general population. Whether this association holds true in primary hypertension and is
independent of renal function and metabolic syndrome is not clear at present.
RESEARCH DESIGN AND METHODS — In a prospective, observational study, 758
untreated hypertensive patients were evaluated at baseline and followed-up for 11 years.
RESULTS — A total of 8,332 person-years of follow-up revealed that slightly elevated uric
acid levels (i.e., 318 mol/l for women and 420 mol/l for men) at baseline were associated
with a signiﬁcantly higher risk of developing diabetes (hazard ratio 3.65 [95% CI 1.99–6.69],
P  0.0001), even after adjustment for several confounding factors such as metabolic syndrome
(2.78 [1.35–5.70], P  0.0054).
CONCLUSIONS — Uric acid is an independent predictor of diabetes in primary
hypertension.
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T
he coexistence of diabetes and hy-
pertension acts as a multiplier of
cardiovascular risk (1). Therefore,
identifying early predictors for the de-
velopment of diabetes in hypertensive
patients could be useful for devising
more effective strategies to reduce car-
diovascular risk. Recent studies provide
both a pathogenetic and epidemiologi-
calrationaleforaroleofserumuricacid
(SUA) in the development of diabetes
(2,3). However, prospective studies in-
vestigating the impact of SUA in the
development of carbohydrate disorders
in primary hypertension are still
lacking.
RESEARCH DESIGN AND
METHODS— Details of the Mi-
croalbuminuria: A Genoa Investigation
on Complications (MAGIC) study have
been described previously (4). In brief, a
total of 1,024 untreated patients with pri-
mary hypertension and without diabetes
were recruited between 1993 and 1997
from among those attending several out-
patient hypertension clinics in the Genoa
areaandwerefollowed-upforamedianof
11.0 years (range 1.2–14.1 years).
Amongtheeligiblepatients,266were
excluded for various reasons, including
current allopurinol treatment and history
of gout or kidney stones. Attendance was
voluntary, and each participant provided
written informed consent. All surveys
wereapprovedbytheethicscommitteeof
our institution.
Duringthebaselinevisit,attheendof
the washout period, if any, height,
weight, blood pressure values, family his-
tory, and lifestyle habits were recorded.
Creatinine clearance was estimated (esti-
mated glomerular ﬁltration rate [eGFR])
by means of the Cockcroft-Gault formula
(5)usingidealbodyweight(6).Metabolic
syndrome was deﬁned according to the
National Cholesterol Education Program
Adult Treatment Panel III (7). Because
waist circumference measurements were
only available for a subset of participants,
wereplacedabdominalobesitywithover-
all adiposity, deﬁned as BMI 30 kg/m
2.
After baseline evaluation, patients
weretreatedonthebasisofcurrentguide-
lines by the referring general practitioner
or specialist until censoring. The number
of events that occurred between baseline
examination and the censoring date (17
June 2006) for living individuals or the
date of death was collected by examining
the records of the Nominative Cause of
Death Registry, the Hospitalization Dis-
charge Records, and the Ligurian Resi-
dent Population Registry. The
completeness of case ﬁndings from the
sample was 98%. When an event was
reported,originalsourcedocumentswere
retrieved and reviewed independently by
two members of the End Point Commit-
tee. Events were coded according to the
World Health Organization’s ICD-9. The
primary end point was the development
ofdiabetesdeﬁnedashospitalizationwith
a diagnosis of type 2 diabetes.
Analyses were performed using Stat-
view for Windows (version 5.0.1; SAS In-
stitute , Cary, NC). Data are means  SD
ormedians(interquartilerange)asappro-
priate. Logarithmically transformed val-
ues of skewed variables were used for the
statistical analysis. Comparisons between
groupsweremadebyANOVAand
2test.
Cox proportional hazards regression was
usedtoestimatethehazardratio(HR)and
95% CI for the relationship between
slightly elevated uric acid (SEUA) level
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P  0.05 was considered statistically
signiﬁcant.
RESULTS— The study cohort was
composed of 758 Caucasian hypertensive
patients (56% men) aged 49  10 years
with neither diabetes, prior cardiovascu-
larevents,norovertnephropathy.During
8,332 person-years of follow-up, 42 pa-
tients developed diabetes; the incidence
rate was 5.0/1,000 person-years. The
mean SD SUA level was 312  90
mol/l (348  84 mol/l in men and
258  72 mol/l in women). As ex-
pected, patients who developed diabetes
were more likely to fulﬁll the criteria for
diagnosis of metabolic syndrome at base-
line (49 vs. 17%; P  0.0001) and
showed higher SUA and albumin-to-
creatinine ratio baseline levels.
Patients included in the highest sex-
speciﬁc quintile (i.e., 318 mol/l if fe-
male and 420 mol/l if male)
constituted the SEUA group and showed
a higher incidence of diabetes (13 vs. 4%;
P  0.001) than the reference group. The
unadjustedHRforthedevelopmentofdi-
abetes was 3.65 (95% CI 1.99–6.69) for
SEUA and remained signiﬁcant in both
men (HR 2.86 [95% CI 1.33–6.17]) and
women (5.85 [2.08–16.47]). Univariate
Cox analysis showed that variations in
BMI (1.21 [1.11–1.31]), serum fasting
glucose (1.05 [1.02–1.08]), triglycerides
(1.012 [1.009–1.014]), HDL cholesterol
(0.97 [0.95–0.99]), SUA (1.34 [1.11–
1.62]), and albumin-to-creatinine ratio
(1.85 [1.04–3.33]) and the presence of
the metabolic syndrome (4.28 [2.25–
8.16]), were all signiﬁcant predictors of
diabetes. The relationship between SUA
and the development of the end point
persistedevenafteradjustmentforseveral
variables, included age, sex, eGFR, com-
ponents of metabolic syndrome and met-
abolic syndrome as a whole (2.78 [1.35–
5.70]; P  0.0054).
The presence of SEUA and/or meta-
bolic syndrome increased the event
rates of diabetes over the 14 years of
follow-up (Ptrend  0.0001) (Table 1).
The independent contribution of SEUA
was stronger in women, with a 5-fold
greater risk of developing diabetes in
women with SEUA and without meta-
bolic syndrome compared with that of
womenwithneitheroftheseriskfactors
(Table 1). Whereas the presence of both
conditions entails an almost 10-fold
higher risk of developing diabetes re-
gardless of sex, the presence of only one
of the two abnormalities is signiﬁcantly
related to diabetes in women but not in
men (Table 1).
CONCLUSIONS— The present
study shows that over long-term follow-
up, SUA is a powerful predictor of inci-
dent type 2 diabetes in primary
hypertension, especially in women. The
excess of risk associated with SEUA was
similar to that observed in the presence
of obesity (3.59, P  0.0001) and com-
parable to that in the presence of meta-
bolic syndrome (4.28, P  0.0001) and
was independent of the presence of
metabolicsyndromeandotherpotential
confounders. Of interest, SEUA proved
to be the only risk factor independently
related to the development of diabetes
in women.
Although our study cannot address
pathophysiological mechanisms, the in-
dependentcontributionofSUAtotherisk
of incident diabetes that we report inte-
grates and supports previous ﬁndings
both in animal models and in clinical
studies (8–10).
The strengths of the present study in-
clude the prospective design and the fact
that it relates to patients not receiving
medication at baseline and at a relatively
low risk of developing diabetes. Our data
do not prove a cause-effect relationship;
however, showing that hypertensive men
with uric acid 420 mol/l and women
with uric acid 318 mol/l have an in-
creased risk of developing diabetes con-
ﬁrms (11,12) and emphasizes the
usefulness of a more widespread, system-
atic evaluation of uric acid in an effort to
guide the management of hypertension,
especially in women.
Table 1—Comparison of 14-year event rates and HRs on the basis of the presence or absence of metabolic syndrome and/or SEUA
Variable
Diabetes
All Men Women
14-year
rates per
100  SD
No.
Events HR (95%CI)* P value HR (95%CI)* P value HR (95%CI)* P value
Unadjusted model
Lower SUA quintiles without
MS 2.7 14 — — — —
SEUA without MS 6.4 6 2.32 (0.88–6.12) 0.0876 1.47 (0.41–5.37) 0.5,527 5.23 (1.05–26.04) 0.0430
Lower SUA quintiles with MS 8.8 8 3.45 (1.43–8.33) 0.0058 2.47 (0.85–7.24) 0.0982 6.81 (1.37–33.75) 0.0188
SEUA with MS 22.7 14 8.85 (3.88–20.20) 0.0001 7.27 (2.65–20.08) 0.0001 14.62 (3.27–65.35) 0.0004
Multivariate model
SEUA with MS 9.31 (3.00–29) 0.0001 11.63 (3.40–40) 0.0001 10.85 (2.2–54) 0.0085
Lower SUA quintiles with MS 4.36 (1.80–10) 0.0016 2.47 (0.76–8.1) 0.1340 6.59 (1.3–33) 0.0210
SEUA without MS 2.75 (1.01–7.2) 0.0462 2.39 (0.62–9.2) 0.2064 5.22 (1.10–26) 0.0433
Age for each 1- year increment 1.05 (1.01–1.1) 0.0150 1.07 (1.01–1.1) 0.0162 — —
Serum glucose 6.1 mmol/l — — 3.35 (1.10–9.8) 0.0269 — —
CovariatesthatwereconsideredpotentialconfoundersoftherelationshipbetweenSEUAanddevelopmentofdiabeteswereincludedinthemultivariatemodels.The
ﬁnalmodelsfortheoptimalpredictionofdiabeteswereﬁtted,ineachsex,bybackwardeliminationofinsigniﬁcantbaselinevariables(P0.05,i.e.,BMI30kg/m
2,
systolic blood pressure, diastolic blood pressure, triglycerides 1.65 mmol/l, HDL cholesterol 1.04 mmol/l in men and 1.29 mmol/l in women, and eGFR
milliliters per minute). The presence of SEUA and/or metabolic syndrome showed a strong, independent relationship to the end-point for the whole cohort and
for women. MS, metabolic syndrome. *Compared with the group with lower sex-speciﬁc quintiles of SUA and without metabolic syndrome.
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